Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences Inc. (NASDAQ: REVB) reported a significant reduction of over 50% in SARS-CoV-2 Delta viral load after treatment with REVTx-99 in three independent in vitro assays. The company has completed its business combination with Petra Acquisition, Inc., effective January 11, 2022, and is listed under symbols REVB and REVBW. The investigational drug REVTx-99 stimulates protective immune responses and is being developed for multiple viral infections, including COVID-19 and influenza. The firm aims to advance its protective therapy amid the ongoing COVID-19 pandemic.